

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

REC'D 14 NOV 2005

WIPO

PCT

## PCT

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To:  
DAVID J. OLDENKAMP  
SHAPIRO & DUPONT LLP  
233 WILSHIRE BOULEVARD, SUITE 700  
SANTA MONIA, CA 90401

Date of mailing  
(day/month/year)

10 NOV 2005

FOR FURTHER ACTION

See paragraph 2 below

Applicant's or agent's file reference

0180.0077

International application No.

International filing date (day/month/year)

Priority date (day/month/year)

PCT/US05/05529

23 February 2005 (23.02.2005)

24 February 2004 (24.02.2004)

International Patent Classification (IPC) or both national classification and IPC

IPC(7): A61K 31/415 and US Cl.: 514/396, 398, 399

Applicant

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

#### 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  
For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US  
Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Facsimile No. (703) 305-3230

Date of completion of this opinion  
28 October 2005 (28.10.2005)

Authorized officer  
Cybille Delacroix-Muirheid  
Telephone No. (571) 272-1600

Form PCT/ISA/237 (cover sheet) (April 2005)

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US05/05529

**Box No. I Basis of this opinion**

1. With regard to the language, this opinion has been established on the basis of:

- ☒ the international application in the language in which it was filed  
☐ a translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- ☐ a sequence listing  
☐ table(s) related to the sequence listing

b. format of material

- ☐ on paper  
☐ in electronic form

c. time of filing/furnishing

- ☐ contained in the international application as filed.  
☐ filed together with the international application in electronic form.  
☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US05/05529

**Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)

Claims 1-14 YES

Claims NONE NO

Inventive step (IS)

Claims 1-14 YES

Claims NONE NO

Industrial applicability (IA)

Claims 1-14 YES

Claims NONE NO

2. Citations and explanations:

Claims 1-14 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the claimed compositions and pharmaceutical composition comprising the described chemical formula as well as the claimed uses of the compositions for inhibiting the growth of prostate cancer cells or a method of inhibiting prostate specific antigen production in a prostate cancer cell. The prior art also fails to disclose or fairly suggest the claimed methods of making the compositions/pharmaceutical compositions as well as methods for antagonizing the function of the ligand binding domain of the androgen receptor polypeptide in a prostate cancer cell.

Claims 1-14 meet the criteria set out in PCT Article 33(4), because the subject matter can be made or used in industry.